| Document |
Document Title |
|
JP2005516918A |
Compounds of Formula (I) wherein R1, R3, R4, R5 and X are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particu...
|
|
JP2005515961A |
Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate M...
|
|
JP2005511569A |
Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, ...
|
|
JP2005511568A |
Provided herein is a compound having the formula (I) (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of q heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic rin...
|
|
JP2005104990A |
To obtain a new agonist of a peptide hormone, vasopressin.A compound represented by formulae 1 or formula 2 is provided. The compound has antidiuretic action and is useful for treating polyuria, incontinentia urinae, and the like.
|
|
JP3635703B2 |
PURPOSE: To prepare a compound useful as a humidifier in cosmetics. CONSTITUTION: This humidifier is a compound of formula I or II {R1 is H or a 1-4C alkyl; R2 is H, COOH; a CO-O-(1-4C alkyl) or CO-NH-R5; R3 and R4 are each H or OH; R5 i...
|
|
JP2005507937A |
Compounds of the formula are useful in treating disease conditions mediated by TNF-alpha, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, g...
|
|
JP2005068088A |
To provide a seven-membered ring ketimine borate scarcely having amine irritating smell, having a property which is very soluble in methanol, used as a curing agent for epoxy resin and useful in various industrial fields including a conv...
|
|
JP3630449B2 |
PURPOSE: To obtain a novel tricyclic compound which has antagonist activity at V1 and/or V2 receptors and exhibits in vivo vasopressin antagonist activity and is useful for treatment of diseases characterized by excess renal reabsorption...
|
|
JP2005505496A |
The invention relates to a bisaryl derivative of the formula I, wherein (R, R) is selected from (H, H), O, (H, CH3), (H, OH) and (H, CN); Ar is substituted phenyl; and A is a group of following formula II, III, IV or V: The compounds of ...
|
|
JP2005505515A |
The present invention relates to new compounds of formula (I) wherein Z, Y, X, P, Q, R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A, m and n are defined as in any one of claims 1 to 3, a process for their preparation and new int...
|
|
JP2005041871A |
To provide an excellent hair papilla cell growth promoting agent having WNT-5A production inhibitory action, more concretely, an excellent hair growth promoting agent or hair tonic.A tetrasubstituted benzene compound expressed by formula...
|
|
JP3621416B2 |
A benzodiazepine derivative of the formula (I): wherein R1 is a bond, -CH2-, -CH2O-, -OCH2-, -SCH2- or a group of the formula: R2 is a lower alkyl, -COOR5, -CONH(CH2)nCOOR5, -CONHSO2R5, -SO2NHCOR5, or an optionally substituted heterocycl...
|
|
JP2005504046A |
The subject of the invention is a composition for the oxidation dyeing of keratinous fibers, in particular human hair, comprising an oxidation base of the para-phenylenediamine type, substituted with a diazacycloheptane radical. The inve...
|
|
JP2005503356A |
The invention concerns novel benzodiazepine derivatives and their uses in the field of therapeutics particularly for treating pathologies involving the activity of a cyclic nucleotide phosphodiesterase. It also concerns methods for prepa...
|
|
JP2005502652A |
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives a...
|
|
JP2005502623A |
A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are us...
|
|
JP2005500988A |
The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceutic...
|
|
JP2004346059A |
To provide a TGR5 (G protein-coupled receptor) receptor agonist useful for treating various diseases.This TGR5 receptor agonist contains a fused ring compound expressed by formula (1) (wherein ring A is an aromatic ring which may be subs...
|
|
JP2004536084A |
The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
|
|
JP2004339061A |
To obtain a new benzene derivative having a vanilloid receptor agonist activity and useful as a medicine such as a prophylactic/ therapeutic agent for pollakiuria/urinary incontinence or an analgesic agent.A compound is represented by fo...
|
|
JP3590590B2 |
The present invention relates to a process for manufacturing diazepine derivatives of the general formula Iwherein R1 is lower alkyl and R2 is hydrogen, or R1 and R2 are together -(CH2)n- and n is 2 or 3; R3 is halogen, lower alkyl, lowe...
|
|
JP2004534017A |
The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheime...
|
|
JP3587849B2 |
PCT No. PCT/EP94/02353 Sec. 371 Date Mar. 22, 1996 Sec. 102(e) Date Mar. 22, 1996 PCT Filed Jul. 18, 1994 PCT Pub. No. WO95/03285 PCT Pub. Date Feb. 2, 1995Compounds of formula (I) (I) wherein the substituents are defined in the specific...
|
|
JP2004532834A |
The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereofwhich have selective histamine-H3 receptor antagonist activity as well as methods for preparing such c...
|
|
JP2004292448A |
To develop a new dye composition having no defect in oxidation bases in conventional technology, and concretely, to obtain a new oxidation base having such good toxicological features and characteristics that the dye composition containi...
|
|
JP2004285069A |
To provide a composition for dyeing a keratin fiber, containing a new oxidation base material which has a toxicity profile better than those of para-phenylenediamine and para-tolylenediamine and simultaneously furnishes the hair with exc...
|
|
JP2004530668A |
A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or -(CH2)n; wherein R is hydrogen or (C1-C6) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selec...
|
|
JP2004529125A5 |
|
|
JP3563738B2 |
An amino acid derivative having an angiotensin I-converting enzyme inhibitor activity, a vasopressin antagonism and an atrial natriuretic peptide hydrolase inhibitor activity, and represented by general formula (I) wherein R<1> represent...
|
|
JP2004526771A |
The present invention provides compounds of the general formulas: wherein Y is NR or -(CH2)n; R is H or alkyl; "Z" represents optionally substituted phenyl or a 6-membered aromatic ring having one nitrogen atom; "W" represents a optional...
|
|
JPWO2002092096A1 |
(3R) -N- (1- (1-tert-butylcarbonylmethyl) -2,3-dihydro-2-oxo-5- (2-pyridyl) -1H-1,4-benzodiazepine-3-yl)- It was confirmed that the antitumor agent of the present invention containing N'-(3- (methylamino) phenyl) urea as an active ingred...
|
|
JP2004521106A |
This invention relates to the novel use of sulfonamide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
JPWO2002026732A1 |
The present invention provides a benzodiazepine derivative represented by the following formula, an analog thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent inhibitory activi...
|
|
JP2004519511A |
The invention relates to the use of pharmaceutical compositions comprising GABA-receptor modulators in ophthalmology, for the prevention and/or treatment of neurodegenerative diseases of the eye, whereby the GABA-receptor modulators are ...
|
|
JP2004518611A |
Aldosterone blockers used for the treatment and prevention of inflammation are disclosed
|
|
JP3526310B2 |
PURPOSE: To provide a specified compd. as a useful intermediate of an antihypertensive agent and high in optical purity by asymmetrically hydrogenating 3-carboxy-3-pyrazoline or the like in the presence of a ruthenium-diphosphine complex...
|
|
JP2004513063A |
The present invention relates to cinnamide compounds of formula (I), in which at least one of R1 to R5 is a "cis-cinnamide" (a) or a "trans-cinnamide" (b) and the other variables are as defined in the claims, that are useful for treating...
|
|
JP2004131477A |
To provide an oil soluble abrasion-preventing, corrosion-preventing and oxidation-preventing agent without containing metal and phosphorus, used for a lubricating oil.This lubricating oil composition contains (a) 0.1-20 % at least one co...
|
|
JP2004512345A |
Disclosed are vesicular drug delivery vehicles, such as liposomes, comprising a targeting ligand which comprises a non-biological, biomitric antagonist to a receptor that is upregulated at a disease site.
|
|
JP2004123595A |
To obtain an azepine compound useful as a luminescent material for an organic EL element and to provide a method for producing the same.The organic EL element contains the azepine compound (I) (X1 and X2 are each cyano group; R1 is a 1-6...
|
|
JP2004511474A |
Compounds of formula (I) are disclosed. The compounds inhibit the action of gamma secretase, and hence find use in the treatment and prevention of Alzheimer's disease.
|
|
JP2004508287A |
This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
JP2004508289A |
This invention relates to novel lactams having the Formula (I):to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit th...
|
|
JP2004505981A |
The invention relates to a method for the preparation of compound of formula (1). The invention further relates to the previously unknown compounds of formulas (5 and 6) as intermediates in the production of benzodiazepines of formula (1).
|
|
JPWO2002030896A1 |
General formula (1) [In the formula, A represents a group- (CH2) n- (n indicates 1 or 2) or a methine (CH) group, and when A is -CH2-, B is a methine group or nitrogen. Indicates an atom, AB is a single bond, when A is (CH2) 2-, B is a n...
|
|
JP2004051614A |
To provide a new vermin-controlling agent, especially an insecticide or acaricide.This vermin-controlling agent contains a substituted amide compound expressed by general formula (1) [wherein, A is carbon atom or the like; G is G-1 or G-...
|
|
JP3497164B2 |
PCT No. PCT/US92/05463 Sec. 371 Date Jun. 26, 1992 Sec. 102(e) Date Jun. 26, 1992 PCT Filed Jun. 26, 1992 PCT Pub. No. WO93/00095 PCT Pub. Date Jan. 7, 1993This invention relates to compounds of the formula: wherein A1 to A5 form an acce...
|
|
JP2004504259A |
The invention provides the use of a compound that inhibits the activity of Janus family kinase 3 (JAK-3), or pharmaceutically acceptable salt thereof; for the manufacture of a medicament for inhibiting c-jun activation in mammalian or av...
|
|
JP2004501904A |
The invention is concerned with novel benzodiazepine derivatives, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds are inhibitors of the human papillomav...
|
